← Leaderboards
Renate B Pilz
University Of California San Diego
$12,707,072
Attributed
$12,707,072
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,707,072 · 6
By mechanism
R01$12,331,972 · 5
R21$375,100 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Paul A Price$2,841,256
Others in their field
Top investigators on “Cyclic Gmp”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$138,433,241
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,746,909
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Putta Neeraja · Fisher Bioservices, Inc.$28,277,912
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,173,207
Research focus
Cyclic GmpNitric OxideCyclic Gmp-Dependent Protein KinasesSignal TransductionNitric Oxide SynthasePublic Health RelevanceGene ExpressionAnalogGenesTreatment StrategyPreventLeadPathway InteractionsOsteoblastsAffectCobinamideAntioxidantsOxidative StressMediatingProteinsOsteogenesisOsteoporosisMitochondriaKnockout Mice
Grant awards (35)
A novel treatment of aortic disease in Marfan Syndrome targeting oxidative stress and PKG dysregulation$731,621
R01 · FY2025 · HL · contact PI
PKG Regulation of Sirtuin 1 as a Novel Treatment Strategy for Age-related Osteoporosis$455,817
R01 · FY2025 · AG · contact PI
A novel treatment of aortic disease in Marfan Syndrome targeting oxidative stress and PKG dysregulation$716,987
R01 · FY2024 · HL · contact PI
PKG Regulation of Sirtuin 1 as a Novel Treatment Strategy for Age-related Osteoporosis$467,062
R01 · FY2024 · AG · contact PI
A novel treatment of aortic disease in Marfan Syndrome targeting oxidative stress and PKG dysregulation$731,621
R01 · FY2023 · HL · contact PI
PKG Regulation of Sirtuin 1 as a Novel Treatment Strategy for Age-related Osteoporosis$467,062
R01 · FY2023 · AG · contact PI
A novel treatment of aortic disease in Marfan Syndrome targeting oxidative stress and PKG dysregulation$731,621
R01 · FY2022 · HL · contact PI
PKG Regulation of Sirtuin 1 as a Novel Treatment Strategy for Age-related Osteoporosis$467,062
R01 · FY2022 · AG · contact PI
PKG Regulation of Sirtuin 1 as a Novel Treatment Strategy for Age-related Osteoporosis$467,062
R01 · FY2021 · AG · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$341,000
R01 · FY2020 · AR · contact PI
Mechanisms of vascular pathology from abnormal protein kinase G signaling$387,500
R01 · FY2019 · HL · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$341,000
R01 · FY2019 · AR · contact PI
Mechanisms of vascular pathology from abnormal protein kinase G signaling$387,500
R01 · FY2018 · HL · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$376,552
R01 · FY2018 · AR · contact PI
Mechanisms of vascular pathology from abnormal protein kinase G signaling$387,500
R01 · FY2017 · HL · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$341,000
R01 · FY2017 · AR · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$47,912
R01 · FY2017 · AR · contact PI
Mechanisms of vascular pathology from abnormal protein kinase G signaling$387,500
R01 · FY2016 · HL · contact PI
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosis$341,000
R01 · FY2016 · AR · contact PI
Testing novel NO/cGMP-based bone-anabolic agents in mouse models of osteoporosis$204,600
R21 · FY2016 · AR · contact PI
Testing novel NO/cGMP-based bone-anabolic agents in mouse models of osteoporosis$170,500
R21 · FY2015 · AR · contact PI
cGMP-dependent Protein Kinase Function in Osteoblast Mechanotransduction$328,104
R01 · FY2014 · AR · contact PI
cGMP-dependent Protein Kinase Function in Osteoblast Mechanotransduction$318,060
R01 · FY2013 · AR · contact PI
cGMP-dependent Protein Kinase Function in Osteoblast Mechanotransduction$334,800
R01 · FY2012 · AR · contact PI
cGMP-dependent Protein Kinase Function in Osteoblast Mechanotransduction$334,800
R01 · FY2011 · AR · contact PI
cGMP-dependent Protein Kinase Function in Osteoblast Mechanotransduction$348,750
R01 · FY2010 · AR · contact PI
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONE$277,912
R01 · FY2008 · AR · contact PI
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONE$284,212
R01 · FY2007 · AR · contact PI
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONE$259,002
R01 · FY2006 · AR · contact PI
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONE$265,272
R01 · FY2005 · AR
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONE$300,032
R01 · FY2004 · AR
REGULATION OF GENE EXPRESSION BY NO/CGMP$241,476
R01 · FY2002 · GM
REGULATION OF GENE EXPRESSION BY NO/CGMP$234,442
R01 · FY2001 · GM
REGULATION OF GENE EXPRESSION BY NO/CGMP$227,701
R01 · FY2000 · GM
REGULATION OF GENE EXPRESSION BY NO/CGMP$3,030
R01 · FY2000 · GM